| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJI.12203 |
| P8608 | Fatcat ID | release_2k7fgvuuprcctjcsx555hs6eju |
| P932 | PMC publication ID | 4024328 |
| P698 | PubMed publication ID | 24494997 |
| P50 | author | Milan Raška | Q38804557 |
| P2093 | author name string | Jan Novak | |
| Jiri Mestecky | |||
| Zina Moldoveanu | |||
| Qing Wei | |||
| Rashada Alexander | |||
| P2860 | cites work | Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 |
| Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro | Q28293679 | ||
| The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells | Q28302792 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. | Q30375160 | ||
| Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces | Q33347255 | ||
| Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection | Q33575368 | ||
| The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions | Q33761318 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region | Q33897480 | ||
| Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design | Q33913898 | ||
| Rational antibody-based HIV-1 vaccine design: current approaches and future directions | Q33937285 | ||
| Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. | Q33967039 | ||
| Mucosal immunoglobulins | Q33988943 | ||
| Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. | Q34619876 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients | Q34637668 | ||
| Humoral immune responses to microbial infections in the genital tract | Q34669747 | ||
| Methods for evaluation of humoral immune responses in human genital tract secretions | Q34676467 | ||
| Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection | Q34693822 | ||
| Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids | Q35075174 | ||
| Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates | Q35076664 | ||
| Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women | Q35093052 | ||
| HIV-1-specific antibody responses during acute and chronic HIV-1 infection | Q35096836 | ||
| Defining the Protective Antibody Response for HIV-1 | Q35109054 | ||
| Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. | Q35603504 | ||
| The antimicrobial activity of lactoferrin: current status and perspectives | Q35820087 | ||
| Immunologic uniqueness of the genital tract: challenge for vaccine development | Q36099546 | ||
| Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus. | Q36150291 | ||
| Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice | Q36440069 | ||
| Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women | Q36547166 | ||
| Neutralizing antibodies in mucosal secretions: IgG or IgA? | Q37017811 | ||
| Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. | Q37063013 | ||
| A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle | Q37108089 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits | Q37444317 | ||
| Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection | Q37724696 | ||
| Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion | Q38290778 | ||
| Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. | Q39637236 | ||
| The common mucosal immune system and current strategies for induction of immune responses in external secretions | Q39663021 | ||
| Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. | Q39933471 | ||
| Intraepithelial cell neutralization of HIV-1 replication by IgA. | Q40437934 | ||
| Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. | Q41697048 | ||
| Extensive variation of human immunodeficiency virus type-1 in vivo | Q43913496 | ||
| Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects | Q44499821 | ||
| Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites | Q45406312 | ||
| Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. | Q45420564 | ||
| Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. | Q45729198 | ||
| Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals | Q45789005 | ||
| Detection of Mucosal Antibodies in HIV Type 1-Infected Individuals | Q58168585 | ||
| Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins | Q67597752 | ||
| Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent western blot immunodetection method | Q72304746 | ||
| Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation | Q73215687 | ||
| IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects | Q73703196 | ||
| False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens | Q73703199 | ||
| Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients | Q74449425 | ||
| Induction and expression of intestinal humoral immunity in HIV-infected individuals: prospects for vaccination against secondary enteric infections | Q74846179 | ||
| Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals | Q81109508 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 600-607 | |
| P577 | publication date | 2014-02-05 | |
| P1433 | published in | American Journal of Reproductive Immunology | Q15761228 |
| P1476 | title | Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women | |
| P478 | volume | 71 |
| Q57035529 | A Phase II Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide -Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization with GBS III |
| Q36753653 | Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women |
| Q27022152 | Challenges in mucosal HIV vaccine development: lessons from non-human primate models |
| Q34034659 | Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection |
| Q38157367 | Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques. |
Search more.